Robert Akpata
A5007543342- Viral Infections and Outbreaks Research
- Parasites and Host Interactions
- Viral Infections and Vectors
- Tuberculosis Research and Epidemiology
- Amoebic Infections and Treatments
- Hepatitis B Virus Studies
- Enhanced Recovery After Surgery
- Cardiac, Anesthesia and Surgical Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Alkaline Phosphatase Research Studies
- Viral gastroenteritis research and epidemiology
- Diagnosis and treatment of tuberculosis
- Surgical site infection prevention
- Pneumonia and Respiratory Infections
- COVID-19 epidemiological studies
- Global Health Workforce Issues
- Helminth infection and control
- Trace Elements in Health
- Parasite Biology and Host Interactions
- SARS-CoV-2 and COVID-19 Research
- Liver Disease and Transplantation
- Travel-related health issues
- HIV/AIDS Impact and Responses
Université de Bordeaux
2024
Inserm
2023-2024
National Institute of Health
2018
Heinrich Heine University Düsseldorf
2016
Clinique Saint Jean
2015
Tuberculosis (TB) is a leading infectious cause of death globally. It the most common opportunistic infection in people living with HIV, and their morbidity mortality. Following TB treatment, surviving individuals may be at risk for post-TB lung disease. The Sentinel Research Network (TB-SRN) provides platform coordinated observational research within International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. This prospective, cohort study will assess treatment post-treatment...
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck's Ervebo (rVSV-ZEBOV) Johnson & Johnson's two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up PREVAC randomized trial (NCT02876328), we report results immunology ancillary study trial. The primary endpoint is to evaluate long-term memory T-cell responses induced by three vaccine regimens: Ad26–MVA, rVSV, rVSV–booster....
The rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus indicated for the prevention of Ebola disease (EVD) caused by Zaire ebolavirus in individuals 12 months age and older.
Abstract Parasitic diseases are relatively rarely diagnosed and treated in Europe. Therefore, European clinicians not familiar with their clinical imaging features. In an era of increased human migration, it is fundamental for to be able identify such diseases. We have recently described the features cystic echinococcosis, schistosomiasis, fascioliasis ascariasis. Here, we report on as well current therapy options infections by small liver flukes: Clonorchis sinensis, Opisthorchis viverrini...
Abstract Introduction The Ebola virus disease (EVD) outbreak in 2014–2016 West Africa was the largest on record and provided an opportunity for large clinical trials accelerated efforts to develop effective safe preventative vaccine. Multiple questions regarding safety, immunogenicity, efficacy of EVD vaccines remain unanswered. To address these gaps evidence base, Partnership Research Vaccines (PREVAC) trial designed. This paper describes design, methods, baseline results PREVAC discusses...
<title>Abstract</title> Background Tuberculosis is a severe disease, not only due to its lethality but also significant morbidity occurring in people living with HIV (PLWH). If factors associated mortality, and unsuccessful treatment related the host are well identified PLWH, there scarce knowledge on disease itself such as bacillary load, extent of lung involvement dissemination other organs. We sought assess whether tuberculosis-related were key patient outcomes PLWH using data from an...
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination.
Background: Surgical site infections (SSIs) are considered as result of the healthcare quality in hospitals. Objective: to study SSI at Saint Jean de Dieu Hospital Tanguieta (SJDHT), prior implementation a permanent monitoring system. Method: transversal, and descriptive with prospective data collection was performed from 1 July 31 janvier 2017 department general surgery SJDHT. The hospital lacks microbiology unit. All patients who underwent during this period were included lasted one month....